(Q37321042)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18992622%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

review article

1 reference

title

Systemic therapy for metastatic renal cell carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18992622%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18992622%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

author name string

Glenn S Kroog

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18992622%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

publication date

1 November 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18992622%20AND%20SRC:MED&resulttype=core&format=json

Urologic Clinics of North America

26 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18992622%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18992622%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18992622%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

687-701; ix

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18992622%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Genetic basis of cancer of the kidney: disease-specific approaches to therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Targeted therapy for metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

The biology of VEGF and its receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Chemotherapeutic strategies for renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

What's past is prologue: lessons learned and the need for further development of allogeneic hematopoietic stem cell transplantation for renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Targeted therapy for metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

New treatment approaches in metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Signal-transduction inhibitors in renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Sunitinib in patients with metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Sorafenib in renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Sorafenib in advanced clear-cell renal-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

When translation meets transformation: the mTOR story

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

7 January 2021

mTOR and cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

TOR signaling in growth and metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2008.07.007

Immunotherapy for advanced renal cell cancer

7 January 2021

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD001425.PUB2

Identifiers

DOI

10.1016/J.UCL.2008.07.007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18992622%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference